Ceribell, Inc. ( ($CBLL) ) has issued an announcement. On January 5, 2026, Ceribell announced that the U.S. Food and Drug Administration granted ...

Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to ...

CeriBell (CBLL) announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for its Large Vessel Occlusion ...

The govt is planning to replace home-based, unequal burn care with a uniform, evidence-based protocol to reduce deaths and ...

Issued on behalf of VentriPoint Diagnostics Ltd. Dana Friesen, CEO of Summit Sciences, brings over 15 years of experience in financial analysis and ROI optimization within the medical device and ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

MarketsandMarkets forecasts the sector will expand at 38.6% annually through 2030 [3], driven by chronic disease burden and data explosion. The FDA cleared over 1,250 AI-enabled medical devices by mid ...

CeriBell Inc. CBLL recently announced that the FDA has given 510(k) clearance for its latest delirium monitoring solution, making it the one and only FDA-cleared solution for continuous tracking of ...

Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring SUNNYVALE, Calif., Dec. 09, ...